<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102594</url>
  </required_header>
  <id_info>
    <org_study_id>TAVAB</org_study_id>
    <secondary_id>2013-005362-19</secondary_id>
    <nct_id>NCT02102594</nct_id>
  </id_info>
  <brief_title>Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)</brief_title>
  <acronym>TAVAB</acronym>
  <official_title>Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to investigate the application of proteasome inhibitor
      Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with
      therapy-refractory antibody-mediated autoimmune diseases. The investigators hypothesis is
      that the proteasome inhibition will lead to reduced antibody titers and improved clinical
      outcome.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment difficulties
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in disease specific antibody titers after application of Bortezomib</measure>
    <time_frame>6 months after end of therapy (6 weeks) compared to baseline (before therapy)</time_frame>
    <description>Change in disease specific antibody titers (anti-ACh for myasthenia gravis, anti-dsDNA for systemic lupus erythematosus, anti-ACPA for rheumatoid arthritis) 6 months after end of Bortezomib therapy (duration 6 weeks) compared to baseline (before therapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease specific antibody titer after Bortezomib application</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
    <description>Change in disease specific antibody titer after Bortezomib application (except at time point 6 months after end of therapy = primary outcome measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (Qol score)</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Activities of Daily Living (Adl score)</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in dose of immunosuppressive co-medication</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in titers of protective antibodies (e.g. measles)</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
    <description>Change in titers of protective antibodies against measles virus, rubella virus, varicella zoster virus, pneumococcus, cytomegalovirus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of antibody producing plasmablasts/cells</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
    <description>Change in number of antibody producing plasmablasts/cells in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of soluble mediators (e.g. IL-6)</measure>
    <time_frame>at regular intervals up to 30 weeks compared to baseline</time_frame>
    <description>Change in concentration of soluble mediators (e.g. IL-6) in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for hospitalisation</measure>
    <time_frame>at regular intervals up to 30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Myasthenia Gravis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Bortezomib (Velcade)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.</description>
    <arm_group_label>Bortezomib (Velcade)</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        (main) Inclusion Criteria:

          -  age 18 - 75 years at screening

          -  ability to give written consent, informed written consent

          -  negative pregnancy test at screening

          -  therapy-refractory Myasthenia Gravis (generalized) or Systemic Lupus Erythematosus or
             Rheumatoid Arthritis

        (main) Exclusion Criteria:

          -  Belimumab therapy within the last 6 months

          -  B-cell-depletion therapy within the last 9 months

          -  heart or kidney insufficiency

          -  known intolerability to Bortezomib

          -  participation in another interventional trial within the last 3 months

          -  liver cirrhosis

          -  preexistent sensory or motor polyneuropathy ≥ degree 2 (NCI CTC AE criteria), within
             14 days before screening

          -  hints on clinically apparent herpes zoster reactivation

          -  active systemic infection, or viral infection (CMV, EBV) within last 6 month before
             screening

          -  serologically active hepatitis B and /or C, known HIV infection

          -  tumor disease currently or within last 5 years

          -  clinically relevant liver, kidney or bone marrow function disorder

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Meisel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité - Universitätsmedizin Berlin, NeuroCure Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Falk Hiepe, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité - Universitätsmedizin Berlin, Internal Medicine / Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite - Universitätsmedizin Berlin, NeuroCure Clinical Research Center</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Internal Medicine / Rheumathology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S1474442216000338?via%3Dihub</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Kohler S, Losen M, Alexander T, Hiepe F, Meisel A. Myasthenia gravis: subgroup classifications. Lancet Neurol. 2016 Apr;15(4):356-7. doi: 10.1016/S1474-4422(16)00033-8.</citation>
    <PMID>26971655</PMID>
  </reference>
  <reference>
    <citation>Kohler S, Märschenz S, Grittner U, Alexander T, Hiepe F, Meisel A. Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial. BMJ Open. 2019 Jan 28;9(1):e024523. doi: 10.1136/bmjopen-2018-024523.</citation>
    <PMID>30696682</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Meisel</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Myasthenia Gravis</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>proteasome inhibitor</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Velcade</keyword>
  <keyword>antibody-mediated autoimmune disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

